Mizuho analyst Ann Hynes raised the firm’s price target on Cardinal Health to $74 from $66 and keeps a Neutral rating on the shares post the Q3 results. The recovery in core business volumes remains a tailwind for the drug distributors, Hynes tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CAH: